Literature DB >> 33108454

Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Amy M Trottier1,2, Lawrence J Druhan3, Ira L Kraft1,2,4, Amanda Lance3, Simone Feurstein1,2, Maria Helgeson5, Jeremy P Segal6, Soma Das5, Belinda R Avalos3, Lucy A Godley1,2,5.   

Abstract

Colony-stimulating factor 3 receptor (CSF3R) encodes the receptor for granulocyte colony-stimulating factor (G-CSF), a cytokine vital for granulocyte proliferation and differentiation. Acquired activating heterozygous variants in CSF3R are the main cause of chronic neutrophilic leukemia, a hyperproliferative disorder. In contrast, biallelic germ line hypomorphic variants in CSF3R are a rare cause of severe congenital neutropenia, a hypoproliferative condition. The impact of heterozygous germ line CSF3R variants, however, is unknown. We identified CSF3R as a new germ line hematologic malignancy predisposition gene through analysis of 832 next-generation sequencing tests conducted in 632 patients with hematologic malignancies. Among germ line CSF3R variants, 3 were abnormal in functional testing, indicating their deleterious nature. p.Trp547* was identified in 2 unrelated men with myelodysplastic syndromes diagnosed at 76 and 33 years of age, respectively. p.Trp547* is a loss-of-function nonsense variant in the extracellular domain that results in decreased CSF3R messenger RNA expression and abrogation of CSF3R surface expression and proliferative responses to G-CSF. p.Ala119Thr is a missense variant found in 2 patients with multiple myeloma and acute lymphoblastic leukemia, respectively. This variant is located between the extracellular immunoglobulin-like and cytokine receptor homology domains and results in decreased G-CSF sensitivity. p.Pro784Thr was identified in a 67-year-old man with multiple myeloma. p.Pro784Thr is a missense variant in the cytoplasmic domain that inhibits CSF3R internalization, producing a gain-of-function phenotype and G-CSF hypersensitivity. Our findings identify germ line heterozygous CSF3R variants as risk factors for development of myeloid and lymphoid malignancies.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33108454      PMCID: PMC7594406          DOI: 10.1182/bloodadvances.2020002013

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  52 in total

1.  Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register.

Authors:  B Cassinat; C Bellanné-Chantelot; A Notz-Carrère; M L Menot; C Vaury; M Micheau; B Bader-Meunier; Y Perel; T Leblanc; J Donadieu; C Chomienne
Journal:  Leukemia       Date:  2004-09       Impact factor: 11.528

2.  Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder.

Authors:  Jane E Churpek; Jacqueline S Garcia; Jozef Madzo; Sarah A Jackson; Kenan Onel; Lucy A Godley
Journal:  Leuk Lymphoma       Date:  2010-10

Review 3.  Somatic mutation panels: Time to clear their names.

Authors:  Amy M Trottier; Marcela Cavalcante de Andrade Silva; Zejuan Li; Lucy A Godley
Journal:  Cancer Genet       Date:  2019-04-26

4.  Identification of ligand-binding site III on the immunoglobulin-like domain of the granulocyte colony-stimulating factor receptor.

Authors:  J E Layton; N E Hall; F Connell; J Venhorst; H R Treutlein
Journal:  J Biol Chem       Date:  2001-07-23       Impact factor: 5.157

Review 5.  Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene.

Authors:  I P Touw; F Dong
Journal:  Leuk Res       Date:  1996-08       Impact factor: 3.156

Review 6.  Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders.

Authors:  Ivo P Touw; Gert-Jan M van de Geijn
Journal:  Front Biosci       Date:  2007-01-01

7.  High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

Authors:  Claude Preudhomme; Aline Renneville; Violaine Bourdon; Nathalie Philippe; Catherine Roche-Lestienne; Nicolas Boissel; Nathalie Dhedin; Jean-Marie André; Pascale Cornillet-Lefebvre; André Baruchel; Marie-Joelle Mozziconacci; Hagay Sobol
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

8.  A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

Authors:  David R Spiciarich; Stephen T Oh; Amy Foley; Seamus B Hughes; Michael J Mauro; Omar Abdel-Wahab; Richard D Press; Rosa Viner; Sarah L Thompson; Qiushi Chen; Parastoo Azadi; Carolyn R Bertozzi; Julia E Maxson
Journal:  Cancer Res       Date:  2018-10-22       Impact factor: 12.701

9.  Rare coding variants pinpoint genes that control human hematological traits.

Authors:  Abdou Mousas; Georgios Ntritsos; Ming-Huei Chen; Ci Song; Jennifer E Huffman; Ioanna Tzoulaki; Paul Elliott; Bruce M Psaty; Paul L Auer; Andrew D Johnson; Evangelos Evangelou; Guillaume Lettre; Alexander P Reiner
Journal:  PLoS Genet       Date:  2017-08-07       Impact factor: 5.917

10.  Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.

Authors:  Maksim Klimiankou; Murat Uenalan; Siarhei Kandabarau; Rainer Nustede; Ingeborg Steiert; Sabine Mellor-Heineke; Cornelia Zeidler; Julia Skokowa; Karl Welte
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

View more
  5 in total

1.  Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms.

Authors:  Borwyn A Wang; Hrishikesh M Mehta; Srinivasa R Penumutchu; Blanton S Tolbert; Chonghui Cheng; Marek Kimmel; Torsten Haferlach; Jaroslaw P Maciejewski; Seth J Corey
Journal:  Leukemia       Date:  2022-08-08       Impact factor: 12.883

2.  Multi-Omics Integration-Based Prioritisation of Competing Endogenous RNA Regulation Networks in Small Cell Lung Cancer: Molecular Characteristics and Drug Candidates.

Authors:  Xiao-Jun Wang; Jing Gao; Qin Yu; Min Zhang; Wei-Dong Hu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

3.  Germline variants drive myelodysplastic syndrome in young adults.

Authors:  Simone Feurstein; Jane E Churpek; Tom Walsh; Sioban Keel; Marja Hakkarainen; Thomas Schroeder; Ulrich Germing; Stefanie Geyh; Michael Heuser; Felicitas Thol; Christian Pohlkamp; Torsten Haferlach; Juehua Gao; Carolyn Owen; Gudrun Goehring; Brigitte Schlegelberger; Divij Verma; Daniela S Krause; Guimin Gao; Tara Cronin; Suleyman Gulsuner; Ming Lee; Colin C Pritchard; Hari Prasanna Subramanian; Daniela Del Gaudio; Zejuan Li; Soma Das; Outi Kilpivaara; Ulla Wartiovaara-Kautto; Eunice S Wang; Elizabeth A Griffiths; Konstanze Döhner; Hartmut Döhner; Mary-Claire King; Lucy A Godley
Journal:  Leukemia       Date:  2021-01-28       Impact factor: 11.528

Review 4.  Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies.

Authors:  Serine Avagyan; Akiko Shimamura
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

5.  Identification of immune-related and autophagy-related genes for the prediction of survival in bladder cancer.

Authors:  Quanfeng Zhu; Lingdi Zhang; Yaping Deng; Leilei Tang
Journal:  BMC Genom Data       Date:  2022-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.